Compare Stocks: FHTX, AUTL, ENTX, and KMDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.71 +0.9%	$2.06	$1.18 ▼ $2.58	$451.15M	2.15	1.78 million shs	396 shs
ENTX Entera Bio	$2.60 +3.9%	$2.89	$0.91 ▼ $4.20	$434.11M	1.4	576,984 shs	784,484 shs
FHTX Foghorn Therapeutics	$1.87 +1.0%	$4.65	$1.79 ▼ $7.61	$108.97M	3.01	347,071 shs	1,932 shs
KMDA Kamada	$7.73 +1.6%	$8.12	$6.55 ▼ $9.35	$444.27M	0.89	79,752 shs	941 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+4.32%	-6.63%	-12.89%	+15.75%	+4.32%
ENTX Entera Bio	+0.40%	-0.40%	-11.35%	+25.00%	-1.57%
FHTX Foghorn Therapeutics	0.00%	-11.48%	-57.57%	-63.51%	-57.47%
KMDA Kamada	-1.17%	-3.68%	-8.54%	+9.99%	+11.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.71 +0.9%	$2.06	$1.18 ▼ $2.58	$451.15M	2.15	1.78 million shs	396 shs
ENTX Entera Bio	$2.60 +3.9%	$2.89	$0.91 ▼ $4.20	$434.11M	1.4	576,984 shs	784,484 shs
FHTX Foghorn Therapeutics	$1.87 +1.0%	$4.65	$1.79 ▼ $7.61	$108.97M	3.01	347,071 shs	1,932 shs
KMDA Kamada	$7.73 +1.6%	$8.12	$6.55 ▼ $9.35	$444.27M	0.89	79,752 shs	941 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+4.32%	-6.63%	-12.89%	+15.75%	+4.32%
ENTX Entera Bio	+0.40%	-0.40%	-11.35%	+25.00%	-1.57%
FHTX Foghorn Therapeutics	0.00%	-11.48%	-57.57%	-63.51%	-57.47%
KMDA Kamada	-1.17%	-3.68%	-8.54%	+9.99%	+11.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	2.86	Moderate Buy	$10.00	486.51% Upside
ENTX Entera Bio	2.83	Moderate Buy	$9.60	269.66% Upside
FHTX Foghorn Therapeutics	2.27	Hold	$6.14	228.67% Upside
KMDA Kamada	3.00	Buy	$13.50	74.76% Upside

Current Analyst Ratings Breakdown

Latest FHTX, AUTL, ENTX, and KMDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	FHTX Foghorn Therapeutics	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target	Outperform ➝ In-Line	$3.00
10/13/2026	FHTX Foghorn Therapeutics	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Hold	$3.00
10/9/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/2/2026	FHTX Foghorn Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$12.00 ➝ $5.00
10/2/2026	FHTX Foghorn Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $2.00
10/2/2026	FHTX Foghorn Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$12.00 ➝ $5.00
10/2/2026	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$13.00 ➝ $5.00
10/1/2026	FHTX Foghorn Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold
10/1/2026	FHTX Foghorn Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral
10/1/2026	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Market Outperform ➝ Market Perform
10/1/2026	FHTX Foghorn Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$5.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$117.39M	3.87	N/A	N/A	$0.67 per share	2.54
ENTX Entera Bio	N/A	N/A	N/A	N/A	$0.29 per share	N/A
FHTX Foghorn Therapeutics	$36.74M	3.02	N/A	N/A	($1.92) per share	-0.97
KMDA Kamada	$180.46M	2.46	$0.61 per share	12.59	$4.68 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	10/29/2026 (Estimated)
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-147.19%	-103.22%	11/13/2026 (Estimated)
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	11/4/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	20.33	13.32	0.65	11.60%	8.37%	5.85%	11/9/2026 (Estimated)

Latest FHTX, AUTL, ENTX, and KMDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	AUTL Autolus Therapeutics	-$0.20	N/A	N/A	N/A	$39.97 million	N/A
11/9/2026	Q3 2026	KMDA Kamada	$0.13	N/A	N/A	N/A	$52.51 million	N/A
11/4/2026	Q3 2026	FHTX Foghorn Therapeutics	-$0.23	N/A	N/A	N/A	$6.39 million	N/A
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.13	1.68%	N/A	34.21%	N/A

Latest FHTX, AUTL, ENTX, and KMDA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	1.04	4.89	4.40
ENTX Entera Bio	N/A	8.98	8.98
FHTX Foghorn Therapeutics	N/A	3.36	3.36
KMDA Kamada	N/A	4.06	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
ENTX Entera Bio	14.11%
FHTX Foghorn Therapeutics	61.55%
KMDA Kamada	20.38%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
ENTX Entera Bio	10.57%
FHTX Foghorn Therapeutics	9.02%
KMDA Kamada	36.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	752	266.16 million	197.76 million	Optionable
ENTX Entera Bio	21	173.92 million	155.54 million	Optionable
FHTX Foghorn Therapeutics	106	59.39 million	54.03 million	Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable

FHTX, AUTL, ENTX, and KMDA Headlines

Recent News About These Companies

Kamada (NASDAQ:KMDA) Stock Price Breaks Below 200 Day Moving Average - Here's Why

October 14 at 3:42 AM | americanbankingnews.com

Kamada (NASDAQ:KMDA) Stock Price Crosses Below Two Hundred Day Moving Average - Time to Sell?

October 14 at 3:39 AM | marketbeat.com

Kamada stock launches two biosimilars as portfolio reaches four

October 8, 2026 | ad-hoc-news.deA

Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel

October 6, 2026 | finance.yahoo.com

Kamada (NASDAQ: KMDA) expands biosimilars portfolio with 2030 revenue guide

October 6, 2026 | americanbankingnews.com

Kamada expands biosimilar portfolio with new launches

October 6, 2026 | grafa.comG

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

October 6, 2026 | globenewswire.com

Kamada Corrects SEC Filing Error and Commits to Clearer Inventory Accounting Disclosures

October 5, 2026 | tipranks.com

Kamada stock gained 1.34 percent as KedRAB demand rose

October 5, 2026 | ad-hoc-news.deA

Kamada Stock Sees Q3 Earnings Estimate Cut at Sidoti

October 2, 2026 | marketbeat.com

Kamada Stock Sees FY2026 Earnings Estimate Lowered at Sidoti

September 29, 2026 | marketbeat.com

Sidoti Brokers Reduce Earnings Estimates for Kamada

September 28, 2026 | marketbeat.com

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

September 27, 2026 | marketbeat.com

Kamada (NASDAQ:KMDA) Sees Strong Trading Volume - Still a Buy?

September 18, 2026 | marketbeat.com

Kamada says KedRAB supplies are adequate as rabies cases rise in U.S.

September 17, 2026 | seekingalpha.com

Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US

September 17, 2026 | finance.yahoo.com

Kamada Confirms KedRAB Supply As U.S. Rabies Exposures Increase

September 17, 2026 | rttnews.com

Kamada says KedRAB supplies are adequate as rabies cases rise in US

September 17, 2026 | msn.com

Kamada Assures Adequate KedRAB Supply as U.S. Rabies Exposures Surge

September 17, 2026 | tipranks.com

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

September 17, 2026 | globenewswire.com

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, AUTL, ENTX, and KMDA Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.70 +0.02 (+0.89%)

As of 09:45 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Entera Bio NASDAQ:ENTX

$2.60 +0.10 (+3.88%)

As of 09:45 AM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Foghorn Therapeutics NASDAQ:FHTX

$1.87 +0.02 (+1.03%)

As of 09:45 AM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Kamada NASDAQ:KMDA

$7.72 +0.13 (+1.64%)

As of 09:43 AM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FHTX, AUTL, ENTX, and KMDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FHTX, AUTL, ENTX, and KMDA Earnings

Compare Dividends

Latest FHTX, AUTL, ENTX, and KMDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FHTX, AUTL, ENTX, and KMDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, AUTL, ENTX, and KMDA Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Entera Bio NASDAQ:ENTX

Foghorn Therapeutics NASDAQ:FHTX

Kamada NASDAQ:KMDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FHTX, AUTL, ENTX, and KMDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FHTX, AUTL, ENTX, and KMDA Earnings

Compare Dividends

Latest FHTX, AUTL, ENTX, and KMDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FHTX, AUTL, ENTX, and KMDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, AUTL, ENTX, and KMDA Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Entera Bio NASDAQ:ENTX

Foghorn Therapeutics NASDAQ:FHTX

Kamada NASDAQ:KMDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools